<DOC>
	<DOCNO>NCT01361269</DOCNO>
	<brief_summary>Few efficient drug malaria treatment available far . Due increase exposure drug due high risk development drug resistant strain Plasmodium falciparum , new drug combination actively investigate . The investigator test efficiency , safety tolerance combine fosmidomycin clindamycin treatment acute uncomplicated malaria child age 3-10 year .</brief_summary>
	<brief_title>Evaluation Fosmidomycin Clindamycin Treatment Acute Uncomplicated Plasmodium Falciparum Malaria</brief_title>
	<detailed_description>Few efficient drug malaria treatment available far . Due increase exposure drug due high risk development drug resistant strain Plasmodium falciparum , new drug combination actively investigate . The goal study assess new drug combination , fosmidomycin-clindamycin . The primary objective study ass compare efficacy , safety tolerance ( site ) fosmidomycin clindamycin co-administered orally three day treatment acute uncomplicated Plasmodium falciparum malaria child Mozambique Gabon . The secondary objective differentiate recrudescent parasitaemia reinfection event recurrent parasitaemia develop within 28-day follow-up period , determine population pharmacokinetics fosmidomycin co-administered orally clindamycin compare vitro sensitivity isolate Plasmodium falciparum fosmidomycin . The trial include 100 child age 3-10 year , divide clinical site Gabon Mozambique .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<criteria>Male female subject age three ten year Body weight ≥12kg Acute ( symptom last less 14 day ) uncomplicated P falciparum malaria Asexual parasitaemia 1,000/µL 200,000/µL Ability tolerate oral therapy Willingness parent guardian provide inform signed consent Symptoms/signs severe malaria , accord WHO criteria ( see appendix I ) Body weight &lt; 12kg Other concomitant plasmodial infection ( P vivax , P ovale , P malariae ) Severe malnutrition weight height &lt; 70 % ( accord WHO table ) clinical kwashiorkor Gastrointestinal disturbance persistent vomit ( &gt; three episode within previous 24 hour ) and/or diarrhoea ( &gt; 5 loose stool precede 24 hour ) Concomitant disease mask assessment response include sickle cell disease severe cardiac , hepatic renal impairment Packed cell volume ( PCV ) arrival &lt; 22 % Adequate antimalarial treatment within previous 7 day Inability tolerate oral therapy Parent guardian deem unsupportive On cotrimoxazole prophylaxis Any known allergy investigational product</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>